// App-Quantinova.ai

1001 : Genetic landscape of resistance to CDK4/6 inhibition in circulating tumor DNA (ctDNA) analysis of the PALOMA3 trial of palbociclib and fulvestrant versus placebo and fulvestrant.

Researchers

Presenter

  • Nicholas C. Turner

Principal Investigators

  • Ben O'Leary

  • Ros Cutts

  • Yuan Liu

  • Sarah Hrebien

  • Xin Huang

  • Matthew Beaney

  • Kerry Fenwick

  • Fabrice Andre

  • Sibylle Loibl

  • Sherene Loi

  • Isaac Garcia-Murillas

  • Cynthia Huang Bartlett

  • Massimo Cristofanilli

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Pfizer Oncology, La Jolla, CA

  • Pfizer Inc, San Diego, CA

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • German Breast Group (GBG), Neu-Isenbug, Germany

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Pfizer Inc, Collegeville, PA

  • Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, IL

Locations

  • Germany

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • Pfizer Inc.

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Cyclin-dependent kinase 4

  • Circulating DNA

Drug/Treatment

  • Fulvestrant

  • Palbociclib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved